Heartflow (HTFL) EBITDA Margin (2024 - 2025)
Heartflow (HTFL) recorded quarterly EBITDA Margin of 49.48% in Q4 2025, up 54.8% quarter-over-quarter from 109.45% in Q3 2025, and up 4413.0% on a YoY basis from 1.1% in Q4 2024.
Heartflow (HTFL) EBITDA Margin (2024 - 2025) Analysis & Trends
Heartflow's EBITDA Margin history runs 2 years deep, the most recent figure standing at 49.48% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 4413.0% year-over-year to 49.48%; the TTM figure through Dec 2025 stood at 67.09% (changed N/A YoY), while the FY2025 annual figure was 66.15%, up 1071.0% from the prior year.
- EBITDA Margin was 49.48% for Q4 2025 at Heartflow, up from 109.45% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 20.51% in Q2 2025 to a low of 109.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 24.83 Bn | 17.52 Bn | 662.02 Mn | 26.39% |
| 2 | BrightSpring Health Services | 13.57 Bn | 12.69 Bn | 482.22 Mn | 3.36% |
| 3 | Healthequity | 7.20 Bn | 6.93 Bn | 256.31 Mn | 29.03% |
| 4 | Hinge Health | 5.42 Bn | 5.11 Bn | 154.23 Mn | 19.09% |
| 5 | 10x Genomics | 4.46 Bn | 3.92 Bn | 106.18 Mn | -11.30% |
| 6 | Doximity | 3.81 Bn | 3.06 Bn | 125.97 Mn | 17.08% |
| 7 | Waystar Holding | 3.52 Bn | 3.36 Bn | 268.04 Mn | 27.87% |
| 8 | Privia Health | 2.94 Bn | 2.57 Bn | 595.71 Mn | 1.25% |
| 9 | Omnicell | 1.76 Bn | 1.59 Bn | 140.36 Mn | 5.44% |
| 10 | Heartflow | 1.24 Bn | 1.06 Bn | 39.06 Mn | -49.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.48% |
| Sep 30, 2025 | -109.45% |
| Jun 30, 2025 | -20.51% |
| Dec 31, 2024 | -93.61% |
| Sep 30, 2024 | -59.35% |
| Jun 30, 2024 | -75.61% |